Ignite Creation Date:
2025-12-24 @ 10:55 PM
Ignite Modification Date:
2025-12-28 @ 2:10 AM
Study NCT ID:
NCT04630769
Status:
COMPLETED
Last Update Posted:
2023-04-03
First Post:
2020-11-11
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
FT516 and IL2 With Enoblituzumab for Ovarian Cancer
Sponsor:
Masonic Cancer Center, University of Minnesota
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-04-02
Start Date Type:
ACTUAL
Primary Completion Date:
2022-01-01
Primary Completion Date Type:
ACTUAL
Completion Date:
2022-01-01
Completion Date Type:
ACTUAL
First Submit Date:
2020-11-11
First Submit QC Date:
None
Study First Post Date:
2020-11-16
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2022-08-23
Results First Submit QC Date:
None
Results First Post Date:
2023-04-03
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-03-27
Last Update Post Date:
2023-04-03
Last Update Post Date Type:
ACTUAL